ReviewAntibiotics (Basel, Switzerland)2021
Efflux Pump Mediated Antimicrobial Resistance by Staphylococci in Health-Related Environments: Challenges and the Quest for Inhibition.
Review in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 103 citations in OpenAlex.
- Metal nanoparticles as next-generation therapeutics against antimicrobial resistance: mechanisms, functionalization, and translational potential.Molecular biology reports · 2026Review
- Integrated In Vitro and In Silico Evaluation of Benzimidazolium Salts: Antioxidant Activity, Anti-MRSA/MSSA Effects, and Antibacterial Gene Expression Analysis.Antibiotics (Basel, Switzerland) · 2026Article
- Genomic Characterization and Virulence Determinants ofAntibiotics (Basel, Switzerland) · 2026Article
- Methicillin-ResistantInternational journal of molecular sciences · 2026Review
- Mechanism and Molecular Design Principles of Cationic Surfactants: From Charge-Driven Membrane Interactions to Next-Generation Quaternary Ammonium Compounds.ChemMedChem · 2026Review
- Molecular insights into efflux pump genes in ciprofloxacin- and methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis clinical isolates from Iraq.Scientific reports · 2026Article
- Nanostructured Lipid Carriers Containing Norfloxacin and 2-Aminothiophene Derivative Reduces Fluoroquinolone Resistance in Multidrug-ResistantPharmaceutics · 2026Article
- Prevalence of Biofilm-Forming and Antibiotic-Resistant Coagulase-Negative Staphylococci Isolated from Hospitalized Patients in an Orthopedic Clinic.Pathogens (Basel, Switzerland) · 2026Article
- Echinomycin, a peptide antibiotic from a new bacterial source and its potential to tackle drug resistance in methicillin-resistant Staphylococcus aureus.Archives of microbiology · 2026Article
- First Report ofMicroorganisms · 2026Article
- The WHO priority list of antibiotic-resistant bacteria: challenges and opportunities for next-generation antimicrobial development.Frontiers in pharmacology · 2026Review
- Occurrence, variability and evolutionary relations of efflux pump determinants across five pathogenicFrontiers in pharmacology · 2026Article
- Effect of flavonoids identified in grape pomace extract on efflux pump inFrontiers in microbiology · 2026Article
- Article
- From biofilms to fibrosis: recent advances in research on the pathological microenvironment linked to ureteral stents and their surface functionalization.Frontiers in bioengineering and biotechnology · 2026Review
- Mechanisms and Evolution of Antimicrobial Resistance in Ophthalmology: Surveillance, Clinical Implications, and Future Therapies.Antibiotics (Basel, Switzerland) · 2025Review
- Beyond antiparasitic activity: elucidating the antibacterial potency of pyrvinium pamoate.Microbiology spectrum · 2025Article
- Characterization and Antimicrobial Resistance Profiles of Biofilm Forming Strains ofMicroorganisms · 2025Article
- Reprogramming resistance: phage-antibiotic synergy targets efflux systems in ESKAPEE pathogens.mBio · 2025Review
- Genotypic and phenotypic characterization ofmSystems · 2025Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The increasing emergence of antimicrobial resistance in staphylococcal bacteria is a major health threat worldwide due to significant morbidity and mortality resulting from their associated hospital- or community-acquired infections. Dramatic decrease in the discovery of new antibiotics from the pharmaceutical industry coupled with increased use of sanitisers and disinfectants due to the ongoing COVID-19 pandemic can further aggravate the problem of antimicrobial resistance. Staphylococci utilise multiple mechanisms to circumvent the effects of antimicrobials. One of these resistance mechanisms is the export of antimicrobial agents through the activity of membrane-embedded multidrug efflux pump proteins. The use of efflux pump inhibitors in combination with currently approved antimicrobials is a promising strategy to potentiate their clinical efficacy against resistant strains of staphylococci, and simultaneously reduce the selection of resistant mutants. This review presents an overview of the current knowledge of staphylococcal efflux pumps, discusses their clinical impact, and summarises compounds found in the last decade from plant and synthetic origin that have the potential to be used as adjuvants to antibiotic therapy against multidrug resistant staphylococci. Critically, future high-resolution structures of staphylococcal efflux pumps could aid in design and development of safer, more target-specific and highly potent efflux pump inhibitors to progress into clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.